JOHNSON & JOHNSON REPORTS 73% PSA RESPONSE RATE WITH INVESTIGATIONAL PASRITAMIG-BASED IMMUNOTHERAPY COMBINATION IN ADVANCED PROSTATE CANCER

Reuters · 1d ago

Please log in to view news